CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II...
Industry: Biotechnology
Sector: Healthcare
Phone: 86 21 6450 1828
Address:
Building 2, 1st Floor No. 466 Yindu Road Xuhui District, Shanghai, China
